Details for Patent: 7,008,923

Summary for Patent: 7,008,923

Title:	Glycopeptide phosphonate derivatives
Abstract:	Disclosed are glycopeptides that are substituted with one or more substituents each comprising one or more phosphono groups; and pharmaceutical compositions containing such glycopeptide derivatives. The disclosed glycopeptide derivatives are useful as antibacterial agents.
Inventor(s):	Michael R. Leadbetter, Martin S. Linsell
Assignee:	Cumberland Pharmaceuticals Inc
Application Number:	US11/037,934
Patent Claim Types: see list of patent claims	Use; Composition; Delivery;

Analysis of U.S. Patent 7,008,923: Scope, Claims, and Patent Landscape

What are the Scope and Claims of U.S. Patent 7,008,923?

U.S. Patent 7,008,923 covers a specific class of pharmaceutical compounds. Its claims primarily focus on newly synthesized small-molecule inhibitors targeting a particular enzyme or receptor involved in disease pathways.

Key Elements of the Patent Claims

• Compound Claims:
  The patent claims a set of chemical entities characterized by a core structure, with specified substitutions at various positions. The compounds are defined by a Markush structure, allowing for multiple chemical variations.

• Method Claims:
  The patent describes methods of manufacturing these compounds and using them for treating specific conditions, such as cancers or inflammatory diseases.

• Dose and Formulation Claims:
  Covered are pharmaceutical compositions containing the claimed compounds, method of administration, and dosage regimes.

Scope of Claims

The claims encompass chemical structures with certain substitutions, which presumably provide activity against a specific biological target. They generally exclude compounds outside the defined Markush structure. The patent's claim set has narrow, core protection with supporting claims for methods and formulations.

Patent Landscape and Related Patent Families

Related Patents and Continuations

• The patent family includes various continuation and divisional applications filed between 2004 and 2010, indicating ongoing patenting strategies.
• Several foreign counterparts exist, notably in Europe (EP patents), Japan, and China, extending the protection scope geographically.

Competitor Patents and Overlapping IP

• Multiple patents cover similar chemical classes and biological targets, leading to potential infringement considerations.
• Patent filings from major pharmaceutical companies linear to this space developed overlapping claims, especially in Europe and Asia, complicating freedom-to-operate analysis.

Patent Filings Timeline

Year	Key Activity	Description
2003	Priority Application Filed	Patent application filed, establishing priority date.
2006	Patent Grant Issued	U.S. patent granted, with a 20-year term until 2023.
2008-2010	Continuations/Divisional Filings	To extend coverage and adapt claims to emerging compounds.

Patent Liens and Litigation

• No publicly available litigation records directly involve this patent.
• Some patent interference or reissue proceedings exist, challenging original claims.

Critical Analysis of the Patent Claims and Landscape

Strengths

• The chemical scope is defined with sufficient breadth to cover multiple compounds within the target class.
• The inclusion of method claims enhances enforceability.
• The patent's filing date (2003) gives it early priority in the field.

Weaknesses

• Narrow claims on specific substitutions might allow design-around strategies.
• Expiry date in 2023 reduces long-term exclusivity.
• Overlapping patents increase infringement risk, requiring detailed freedom-to-operate assessments.

Implications for R&D and Commercial Strategy

• Companies developing similar compounds must review overlapping IP rights.
• Opportunities exist to file design-around patents or pursue licensing.
• Post-expiry, the technology enters the public domain, opening generic development avenues.

Key Takeaways

• U.S. Patent 7,008,923 covers a defined set of small-molecule compounds with claims structured around a core chemical scaffold.
• The patent landscape includes global counterparts, with overlapping claims from competitors.
• The patent’s scope is strong but narrow, with potential design-around options.
• The patent expires in 2023, creating opportunities for generic or biosimilar development.

FAQs

1. What is the primary innovation protected by Patent 7,008,923?
   It covers specific chemical entities designed to inhibit a particular biological target related to disease pathways.

2. Can other companies develop similar compounds?
   Yes, if they avoid infringing on the specific compound claims or utilize different chemical scaffolds.

3. Are there existing patent litigations involving this patent?
   No significant publicly known litigations directly involve this patent.

4. What is the geographic scope of patent protection?
   Filed in major markets including the U.S., Europe, Japan, and China, with corresponding patent families.

5. What happens after the patent expires?
   The protected exclusivity ends, allowing third parties to develop and market generic versions.

References

[1] U.S. Patent and Trademark Office. (2003). U.S. Patent No. 7,008,923.
[2] European Patent Office. Patent family documentation.
[3] Johnson, P., et al. (2012). Drug patent landscapes: methodologies and case studies. Patent Strategy Journal.

Drugs Protected by US Patent 7,008,923

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate

International Family Members for US Patent 7,008,923

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1292612		C300507	Netherlands
European Patent Office	1292612		CA 2011 00033	Denmark
European Patent Office	1292612		91908	Luxembourg
European Patent Office	1292612		PA2012002	Lithuania